

Ralton Australian Shares Monthly Report July 2015

Investment Profile

A Professionally Managed Portfolio of Australian Shares

The Ralton Australian Shares model portfolio is a separately managed account, or SMA, actively managed by Ralton Asset Management (Ralton). SMAs are professionally managed portfolios of direct shares whereby the investor receives beneficial ownership of the underlying securities.

Investment Objective

The objective of the Ralton Australian Shares SMA is to to provide investors with long-term capital growth and some tax effective income from a concentrated portfolio of Australian shares. The Portfolio aims to deliver a return superior to that of the market over periods of five years or longer while at the same time seeking to minimise the risk of investment capital loss.

Key Portfolio Features			
Inception	1 February 2008		
Benchmark	S&P/ASX 300 Accumulation Index		
Authorised Investments	Companies in the S&P/ASX 300 Index or those amongst the top 300 by size.		
Number of Stocks	20-35		
Cash Allocation	0% to 10%		
Tracking Error	3% to 6%		
Investment Horizon	At least 5 years		
Ratings	RNINGSTAR Approved tonee: Risearch		

Performance

Return %	1m	3m	1yr	3yrs	5yrs	Incept*
Ralton Aust Shares	5.33	1.14	16.77	20.20	12.57	7.86
Income Return	0.00	0.63	3.82	4.00	4.28	4.35
Growth Return	5.33	0.51	12.95	16.20	8.29	3.51
S&P/ASX 300 Accum. Index	4.31	-0.81	5.51	14.75	9.42	4.50
Difference	1.02	1.95	11.26	5.45	3.16	3.36

The Portfolio is designed for investors who

- Seek long term capital growth & some tax-effective income
- Expect consistent above market returns
- Have a long term investment horizon of at least five years and accept the risk of equity markets.

Portfolio Structure

No.	Company Name	ASX Code
1	National Australia Bank Limited	NAB
2	Commonwealth Bank of Australia	CBA
3	CSL Limited	CSL
4	Westpac Banking Corporation	WBC
5	ANZ Banking Group Limited	ANZ
6	QBE Insurance Group Limited	QBE
7	Aristocrat Leisure Limited	ALL
8	Incitec Pivot Limited	IPL
9	BHP Billiton Limited	ВНР
10	Woolworths Limited	WOW

GICS Sector	Ralton	Index	+/-
Consumer Discretionary	15.2%	4.4%	10.8%
Health Care	9.9%	6.3%	3.6%
Materials	17.1%	14.0%	3.2%
Information Technology	2.1%	1.0%	1.1%
Energy	5.3%	4.8%	0.5%
Industrials	6.8%	7.3%	-0.6%
Utilities	1.5%	2.1%	-0.6%
Consumer Staples	5.9%	6.7%	-0.8%
Financials (ex-Property)	34.2%	39.4%	-5.2%
Telecommunication Services	0.0%	5.9%	-5.9%
Property	1.9%	7.9%	-6.0%
Total	100.0%	100.0%	



Month in Review

Performance Summary

- The S&P/ASX 300 Accumulation Index rose in July, adding 4.31%, with Healthcare and Consumer Staples the top performing sectors.
- The Ralton Australian Shares Model Portfolio gained 5.33% for the month, outperforming the benchmark by 1.02%.
- For the month, the portfolio's overweight to both Consumer Discretionary and Health Care added value to the portfolio.

Portfolio Commentary

Monthly Performance Attribution

Top Contributors	Positioning	Key Detractors	Positioning
Asciano Ltd	Overweight	Transpacific Industries	Overweight
BlueScope Steel Ltd	Overweight	Incitec Pivot	Overweight
iSelect Limited	Overweight	Coca-Cola Amatil	Overweight

Positive Contributors

Shares in Asciano Limited (AIO, +22.3%) were boosted by a takeover bid from Brookfield Investment Management which offered \$9.05 per share for the company. The offer price is a mixture of cash and shares in US-listed Brookfield Investment Partners. Asciano disclosed the offer to the market following media speculation, noting the Brookfield proposal was highly conditional and subject to a range of matters, including due diligence. Like many takeovers, there's some water to flow under the bridge, hence we elected to take some profits in AIO. We have a very positive view of AIO's assets and believe there's good reason for a bid by Brookfield (and potentially others), hence we maintain a material stake in AIO.

After a recent period of underperformance, shares in Bluescope Steel (BSL, +21%) rebounded strongly in July. The shares have been under pressure in recent times due to excess steel production capacity in the region pressuring steel prices, which in turn is negative for BSL's exported and domestic steel sales from Port Kembla in NSW. However, these pressures are likely to drive change, specifically the potential for BSL to close or downsize their Port Kembla steel production, an option BSL didn't deny in a public release. Such a measure would significantly improve the profitability of the group, given BSL's Asian,

American and, to a lesser extent, NZ businesses hold quite strong industry positions. We expect an update from BSL on its long-term plans for its operations with the August full-year profit results.

iSelect (ISU, +22%) rose strongly after it announced the repayment of a loan from NIA (owner of health.com.au). This loan has been a cause for concern to the market for some time. In a three-way deal, Geelong-based private health insurance company, GMHBA acquired the health. com.au business, essentially paying a little over \$40m for the insurance clients of NIA. NIA in turn, used these monies toward repayment of the loan from ISU. For ISU, even though the \$42m fell slightly short of the value of the loan, it removed a key overhang from the stock. Importantly, GMHBA, will continue to market health.com. au product via ISU and will also add their main brand to the iSelect product offering. In this sense, it's a double win for ISU as they've been repaid and have expanded their current health insurance offering. ISU will soon hold approximately \$100m in net cash and we expect will use these monies toward a share buyback. We expect to hear more about capital management and dividends at the fullvear result.

Underperformers

Waste services company, Transpacific Industries (TPI, -7.8%), underperformed the market and weighed on portfolio returns. Recent years have been quite disruptive for TPI, with the business undergoing management change, asset sales and substantial organizational change. We remain optimistic on the outlook for the transformation of the business over the next few years. In particular, a revamped sales model should drive improved asset utilisation, and therefore drive profit growth. In July, TPI appointed Vik Bansal to the position of CEO. Mr Bansal has most recently headed Valmont Industries in the US, however he has considerable experience in corporate Australia. We expect to hear more about his plans for the company with the full-year results in August.

Global explosives and fertilizer manufacturer, Incitec Pivot (IPL, -6.0%), also weighed on portfolio returns for the month, with investors focused on gas supply issues at their Queensland Moranbah plant. The plant is relatively new and is responsible for the production of ammonia nitrate for Queensland customers. Specifically, the plant's gas supplier, Arrow (a JV between Petro China and Shell), has encountered issues with their gas production, which in turn has resulted in reduced gas supply to all their customers, including the IPL plant. This has forced IPL to curtail production forcing them to source alternative supply for their own customers at additional cost. We understand Arrow's contractual obligations require them to make every effort to improve the gas supply problem



and that the incentives to do so are significant. While not ideal, the impact on IPL as a whole is modest, however, investors were all the same unnerved and the stock sold down.

Coca-Cola Amatil (CCL, +1.4%) was largely flat for the month and hence underperformed against the broader rise in the market. CCL is part way through a multi-year transformation and we expect there will be ups and downs along the way. We are attracted to the solid and sustainable dividend (given the strong free cash flow, near-term decline in capex and the recapitalisation of its Indonesian operations) and the turnaround of the business being put in place by Alison Watkins (Managing Director).

Portfolio Adjustments

During the Month we...

SOLD: Sonic Healthcare (SHL)

BOUGHT: nil

Portfolio Additions & Material Adjustments

There were no new stock additions to the portfolio in July. We did, however, increase our position in IPL, reflecting our view that reaction to the gas supply issue, described above was an over-reaction.

Portfolio Additions & Material Adjustments

We disposed of our holding in Sonic Healthcare (SHL). Shares in the global pathology company have fared well in recent times, boosted by the recent acquisition of the Switzerland-based business, Medisupport, for \$A445m. Conditions in the company's US operations are also likely to have been improving if peer results for US-listed Quest and Labcorp are any guide. Despite this, pathology volumes in Australian have remained somewhat below trend, marking a reasonable headwind for group profits. This, together with the valuation of SHL, reached the point where we felt that an outright sale was justified.

We also reduced our holding in two other stocks, Ardent Leisure (AAD) and Asciano Limited (AIO). The latter had been boosted by the potential acquisition by Brookfield Infrastructure and, given the rise in the share price, some uncertainty as to the timing of a formal bid and the nature of the offer, we elected to take some profits.



Investment Approach

A Three Stage Investment Process

Intensive bottom-up research is the cornerstone of the entire process, supplemented by top-down economic and thematic views. The process is disciplined and consistently applied, using a number of proprietary qualitative and quantitative techniques to ensure that targeted companies have been thoroughly scrutinised. The aim is to uncover undervalued businesses. The companies that Ralton typically invests in are those with strong and reliable management, good profit and dividend growth expectations, reasonably predictable future profits and cash flows, and a very clear business model.

Stage 1: Defining the Investment Universe (Screening)


The first stage of the process is to narrow the number of stocks in the investment universe by applying a number of screens. This approach systematically eliminates companies that do not meet certain minimum standards, allowing the Investment team to focus more intensely on companies of potential interest.

Stage 2: Bottom-up Fundamental Company Research

Ralton's research programme is focused on understanding the key drivers of business performance and returns, namely people, operations, products and services, and market dynamics. For companies remaining in the Investment Universe, a detailed assessment is made of executive management, interviews competitors and suppliers, reviews financials, and forms a clear view on the outlook for the company's industry.

Stage 3: Portfolio Construction

Risk management and capital preservation are key themes underlying the portfolio construction framework. With a focus on actively managing down-side portfolio risk for investors, Ralton constructs an efficiently diversified portfolio of high quality, undervalued companies, and invests for the long term (typically 3 to 5 years) in an effort to maximise after tax-returns.



About the Manager

Ralton Asset Management is partnered with Copia Investment Partners, an administration and distribution specialist providing a range of tailored services to each of our leading boutique investment partners.

Ralton is a Value manager with a fundamental investment approach designed to identify quality businesses trading at a considerable discount to valuation. The process is guided by three fundamental beliefs:

- Markets are not perfectly efficient and the true value of a business is not always reflected in its share price;
- Undervalued companies can be identified through detailed and intensive research; and
- Capital preservation is critical to wealth creation.

The Investment Team

Andrew Stanley *BEc, LLB, ACA, FFin, MA AppFin* Head of Australian Equities, Ralton Model Portfolios

Andrew Stanley is the lead portfolio manager for the Ralton portfolios. He is supported by a dedicated and highly experienced team of investment professionals each with an average 18 years investment experience. Andrew has been working in financial markets for more than 24 years, including the past 7 years managing the Ralton portfolios. Prior to Ralton, he was an Executive Director at UBS in Hong Kong, and over the course of his career has held senior positions with major investment institutions in Melbourne, Hong Kong, Tokyo and New York. Andrew started his career at Arthur Andersen in Melbourne.

Roger Walling *BOptom, MBB*Portfolio Manager, Ralton Model Portfolios

Roger Walling is responsible for stock coverage of several industry sectors and assists with the portfolio management process. He has over 12 years of direct funds management experience, including the past 7 years managing the Ralton portfolios. Previous to Ralton, Roger was a shareholder and employee of Cinnabar Equities, a Global Healthcare Fund. In his role as a Senior Analyst, he had sub-sector and stock investment decision responsibility. Prior to his career in financial markets, Roger practiced as an Optometrist.

For Further Information

Financial advisers seeking additional information can contact Ralton Adviser Services at:

Name: John Clothier Phone: 02 8216 0782 Mobile: 0408 488 549

Email: jclothier@copiapartners.com.au

This report provides general information only and does not take into account the investment objectives, financial circumstances or needs of any person. To the maximum extent permitted by law, Ralton, its directors and employees accept no liability for any loss or damage incurred as a result of any action taken or not taken on the basis of the information contained in the report or any omissions or errors within it. Before making an investment decision you should consider the latest PDS or FSG and assess whether the product and/or service is appropriate for you. It is advisable that you obtain professional independent financial, legal and taxation advice before making any financial investment decision. Ralton does not guarantee the repayment of capital, the payment of income, or the performance of its investments. Performance of the Ralton Wholesale SMA Service (PDS dated December 2009) is based on theoretical portfolio tracking of the model portfolio and is gross of investment management & administration fees, but net of transaction costs. Quoted performance is annualised for periods of 1 year or greater.